Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. regarding allegations of securities fraud and unlawful business practices related to its product, DCCR [2][3]. Group 1: Class Action Details - Investors who suffered losses from their investment in Soleno are encouraged to contact Pomerantz LLP to join the class action lawsuit [1]. - The deadline to request appointment as Lead Plaintiff is May 5, 2026, for those who purchased Soleno securities during the Class Period [2]. Group 2: Product and Market Impact - Scorpion Capital published a report on August 15, 2025, labeling DCCR as overpriced and potentially unsafe for children, leading to a stock price drop of $5.73 per share, or 7.41%, closing at $71.63 [2][3]. - Following the disclosure of a patient death related to DCCR on September 10, 2025, Soleno's stock fell by $13.49 per share, or 19.21%, to close at $56.72 [3]. - On November 4, 2025, Soleno reported an 8% discontinuation rate of DCCR due to adverse effects, which the CEO attributed to the negative impact of the Scorpion report on the product's launch trajectory [4]. - The stock price further declined by $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [5].

England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the US drugmaker https://t.co/fWXon8Qsap ...

Core Viewpoint - The law firm Kirby McInerney LLP is reminding investors of Corcept Therapeutics Incorporated about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's securities during a specified class period [1]. Summary by Sections Lawsuit Details - The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" for FDA approval, while the FDA had raised concerns about the adequacy of clinical evidence [3]. - Corcept communicated confidence in the NDA submission, stating there were no anticipated impediments to approval, despite known risks regarding the NDA's approval status [3]. Impact of FDA Communication - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) indicating it could not assess a favorable benefit-risk profile for relacorilant without additional evidence, leading to a significant drop in share price by $35.40, or approximately 50.4%, from $70.20 to $34.80 [4]. - Following the end of the class period, the FDA released a redacted CRL detailing concerns about the clinical studies' sufficiency, resulting in a further decline in share price by $4.74, or approximately 10.6%, from $44.61 to $39.87 [5].

点击小程序查看报告原文 Abstract 摘要 通过"跨国公司成长启示录"，我们希望总结跨国龙头的成功经验，为中国企业的全球化发展提供参考。第一篇主要探讨跨国公司的发展历程及其在全球经 济中的重要性， 本篇报告重点 关注 美国、欧洲、日本三个区域跨国公司的发展情况， 将从企业为何出海、数说跨国公司、典型行业（选取美国科技、欧 洲医药、日本汽车）分别展开。 基于对美欧日跨国公司的比较，我们发现虽然三大经济体企业出海的时代背景各异，但是 底层逻辑上呈现高度一致性，即突破增长天花板、规避贸易壁 垒、全球范围成本套利。 与此同时，不同经济体依托各自资源禀赋、产业根基、制度框架，全球化历程走出不同的发展路径。我们总结如下： 美国：聚焦高附加值，技术引领全球。 1）从出海必要性而言，美国反垄断监管限制大企业的国内发展空间，是企业海外扩张的重要原因。另外，追求生 产要素最优配置是跨国公司构筑全球竞争力的基础逻辑，近年来提高供应链安全成为海外投资布局的重要考量。2）美国凭借全球领先的研发创新体系、 完善的知识产权保护制度、成熟的科技成果转化机制，在高附加值领域构筑技术护城河，科技行业最为典型。我们认为 ①建立领先优势并掌控全 ...

Core Viewpoint - Collegium Pharmaceutical is expanding its position in the ADHD market through the acquisition of AZSTARYS and related subsidiaries from Corium Therapeutics [2] Group 1: Acquisition Details - The acquisition of AZSTARYS significantly enhances Collegium's portfolio in the ADHD sector [2] - The call includes participation from key executives, including the President and CEO, Chief Commercial Officer, and Chief Financial Officer, indicating a strong leadership presence for the discussion [2] Group 2: Investor Communication - The company emphasizes that the information presented is not promotional and includes forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995 [3] - There is a caution regarding the potential differences between future results and current expectations, highlighting the inherent risks and uncertainties [4]

In this article, we will look at the 12 Best Long Term Stocks to Invest In According to Billionaires.On March 17, Ed Yardeni, Yardeni Research president, appeared on CNBC’s ‘Squawk Box’ to talk about the impact of the Iran war, the latest market trends, and the state of the economy.He says he is more risk-averse, at least for the near-term, and stated that everybody on Wall Street is trying to be a military expert in this fog of war, when actually, even the military experts cannot accurately predict where t ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by May 4, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, particularly downplaying the significance of human factors in the use of its sublingual film [5]. - The lawsuit claims that when the true details were revealed, investors suffered damages [5].

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][38] - The adjusted EBITDA margin improved to 29%, up from 18% in the prior year period, indicating significant progress in profitability [6][45] - GAAP net income for the quarter was $1.5 million, compared to a net loss of $0.6 million in the prior year [46][47] Business Line Data and Key Metrics Changes - The launch of Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with both Increlex and Galzin exceeding initial expectations [5][38] - Alkindi Sprinkles continued to perform strongly, contributing to the overall revenue increase [5][38] - The company expects adjusted gross margins to be comfortably above 70% for the full year, with potential to reach between 75% and 80% in the coming years [39][40] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential patient base significantly beyond initial estimates [10][11] - The company anticipates a peak sales forecast of $30 million to $50 million for DESMODA, with initial demand showing strong traction [10][11] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S. and has set new long-term goals, including reaching a $200 million revenue run rate by the end of 2027 [32][33] - The company plans to optimize the distribution model for HEMANGEOL to improve operational efficiency and margin performance [20][21] - Eton is focused on maintaining profitability while pursuing growth, with a target of achieving a 50% adjusted EBITDA margin by 2028 [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for existing products and the successful integration of new acquisitions, including HEMANGEOL and DESMODA [31][60] - The company expects to generate significant operating cash flow throughout 2026 and beyond, indicating a positive outlook for financial health [48] Other Important Information - Eton's acquisition of HEMANGEOL was completed for $14 million in cash, avoiding dilution or incremental debt, which is expected to enhance earnings [24] - The company is preparing for a pilot initiative targeting adult endocrinologists for DESMODA, assessing the opportunity over the next 90 days [10] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's pace to peak sales - The launch of DESMODA has gone well, with expectations for quicker peak sales compared to previous products due to the specific unmet need it addresses [53][54] Question: Cash flow conversion from EBITDA in 2026 - The company anticipates being firmly in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million run rate by end of 2027 - Management is confident that the existing product portfolio, including HEMANGEOL and DESMODA, will contribute significantly to achieving this goal [59][60]